|
A population-based study of pelvic serous carcinoma in Sweden: Primary site, FIGO stage and survival. |
| |
Elisabeth Avall-Lundqvist |
Honoraria - Boehringer Ingelheim; Merck Sharp & Dohme; Roche Pharma AG |
Consulting or Advisory Role - AstraZeneca |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Probi (Inst); Roche Pharma AG (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Astellas Pharma; Merck; Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |